What is the appropriate cefdinir dose per kilogram for a 7‑year‑old child being treated for impetigo?

Cefdinir Dosing for Impetigo in a 7-Year-Old

For impetigo in a 7-year-old child, administer cefdinir at 7 mg/kg every 12 hours (twice daily) for 10 days, with a maximum total daily dose of 600 mg. 1

Dosing Specifics

The FDA-approved dosing for uncomplicated skin and skin structure infections (which includes impetigo) in pediatric patients is:

• 7 mg/kg every 12 hours for 10 days 1
• Maximum daily dose: 600 mg total per day
• Must be given twice daily - once-daily dosing has NOT been studied for skin infections 1

Practical Dosing Example

For a typical 7-year-old weighing approximately 23 kg (50 lbs):

• Dose = 7 mg/kg × 23 kg = 161 mg per dose
• Given every 12 hours (twice daily)
• Using 250 mg/5 mL suspension: approximately 3.2 mL per dose

Why This Regimen

The IDSA guidelines for skin and soft tissue infections do not specifically list cefdinir as a first-line agent 2. The guidelines recommend:

• Cephalexin 25-50 mg/kg/day in 4 divided doses as the preferred oral cephalosporin for non-purulent SSTI
• Dicloxacillin 25-50 mg/kg/day in 4 divided doses (though noted as "not used much in pediatrics")

However, cefdinir is FDA-approved for this indication and clinical studies demonstrate excellent efficacy. A comparative trial showed cefdinir 7 mg/kg twice daily achieved a 98.3% clinical cure rate for pediatric skin infections including impetigo, with 99.4% microbiological eradication 3.

Important Caveats

MRSA Coverage: Cefdinir does NOT cover methicillin-resistant Staphylococcus aureus (MRSA). If MRSA is suspected or confirmed:

• Switch to clindamycin 30-40 mg/kg/day in 3 divided doses 2
• Or trimethoprim-sulfamethoxazole 8-12 mg/kg/day (based on TMP component) in 2 divided doses 2

When to Consider Alternative Agents:

• Widespread lesions or systemic signs → consider systemic antibiotics per IDSA guidelines
• Purulent lesions with concern for MRSA → use anti-MRSA agent
• Treatment failure after 48-72 hours → obtain cultures and consider MRSA coverage

Administration Details

• Can be given with or without food - food reduces absorption but not clinically significant 1
• Suspension remains stable for 10 days at room temperature after mixing 1
• Shake well before each dose

Expected Adverse Effects

Most common side effects (from clinical trials):

• Diarrhea: 8% of patients 3
• Generally well-tolerated with 16% experiencing any adverse event 3

The twice-daily dosing requirement is critical - do not use once-daily dosing for skin infections as this has not been validated in clinical studies 1.